Like-To The Moon - Tiger Brokers Online Investing Community - To The Moon

8
Comment
Favorite

Travis.s
2022-07-07

Like

After-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning

After-Hours Stock Movers:CytomX Therapeutics, Inc. (Nasdaq: CTMX) 28% LOWER; announced that the Phas

After-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

8

Report

Comment

Top
Latest

ToTheM00N
·2022-07-07
Ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9079973140,"tweetId":"9079973140","gmtCreate":1657149579080,"gmtModify":1676535957095,"author":{"id":4118915332339292,"authorId":4118915332339292,"authorIdStr":"4118915332339292","name":"Travis.s","avatar":"https://community-static.tradeup.com/news/00534a485f2442fcbd6abde00786671d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.89%","individualDisplayEnabled":0},"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9079973140","repostId":2249491595,"repostType":2,"repost":{"id":"2249491595","pubTimestamp":1657149169,"share":"https://www.laohu8.com/m/news/2249491595?lang=&edition=full","pubTime":"2022-07-07 07:12","market":"us","language":"en","title":"After-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning","url":"https://stock-news.laohu8.com/highlight/detail?id=2249491595","media":"StreetInsider","summary":"After-Hours Stock Movers:CytomX Therapeutics, Inc. (Nasdaq: CTMX) 28% LOWER; announced that the Phas","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p><a href=\"https://laohu8.com/S/CTMX\">CytomX</a> Therapeutics, Inc. (Nasdaq: CTMX) 28% LOWER; announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR) of greater than 10 percent by central radiology review. Praluzatamab ravtansine is a DM4-conjugated, conditionally activated antibody-drug conjugate (ADC) targeting CD166 and is wholly owned by CytomX.</p><p>Veru, Inc. (NASDAQ: VERU) 19% HIGHER; Adds to 13% intra-day gains after the publication of Phase 3 data demonstrating that Sabizabulin treatment significantly reduced deaths in high-risk hospitalized COVID-19 patients.</p><p>USANA Health Sciences, Inc. (NYSE: USNA) 10% LOWER; announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022. The Company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be approximately $1.05, which compares with $1.87 during the second quarter of 2021. (Consensus sees Q2 EPS of $1.26 on revenue of $272.8 million)</p><p>Avalo Therapeutics, Inc. (Nasdaq: AVTX) 8% LOWER; announced a one-for-twelve reverse stock split of the Company&#39;s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022.</p><p>Bed Bath &amp; Beyond (NASDAQ: BBBY) 7% HIGHER; Interim CEO Sue Gove and two directors buy stock.</p><p>GameStop Corp. (NYSE: GME) 7% HIGHER; announced that its Board of Directors has approved and declared a four-for-one split of the Company’s Class A common stock in the form of a stock dividend.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-07 07:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20298810><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:CytomX Therapeutics, Inc. (Nasdaq: CTMX) 28% LOWER; announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive (HR+)/human ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20298810\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4547":"WSB热门概念","BBBY":"3B家居","BK4178":"家庭装饰零售"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20298810","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2249491595","content_text":"After-Hours Stock Movers:CytomX Therapeutics, Inc. (Nasdaq: CTMX) 28% LOWER; announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-non-amplified breast cancer (Arm A) met its primary efficacy endpoint of confirmed objective response rate (ORR) of greater than 10 percent by central radiology review. Praluzatamab ravtansine is a DM4-conjugated, conditionally activated antibody-drug conjugate (ADC) targeting CD166 and is wholly owned by CytomX.Veru, Inc. (NASDAQ: VERU) 19% HIGHER; Adds to 13% intra-day gains after the publication of Phase 3 data demonstrating that Sabizabulin treatment significantly reduced deaths in high-risk hospitalized COVID-19 patients.USANA Health Sciences, Inc. (NYSE: USNA) 10% LOWER; announced preliminary results for the second quarter ended July 2, 2022, and provided an updated outlook for fiscal year 2022. The Company anticipates that second quarter 2022 net sales will be approximately $265 million, which compares with $337 million in the prior-year period. Earnings per share for the quarter are expected to be approximately $1.05, which compares with $1.87 during the second quarter of 2021. (Consensus sees Q2 EPS of $1.26 on revenue of $272.8 million)Avalo Therapeutics, Inc. (Nasdaq: AVTX) 8% LOWER; announced a one-for-twelve reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022.Bed Bath & Beyond (NASDAQ: BBBY) 7% HIGHER; Interim CEO Sue Gove and two directors buy stock.GameStop Corp. (NYSE: GME) 7% HIGHER; announced that its Board of Directors has approved and declared a four-for-one split of the Company’s Class A common stock in the form of a stock dividend.","news_type":1},"isVote":1,"tweetType":1,"viewCount":321,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":102735296,"gmtCreate":1657150077328,"gmtModify":1663253612252,"authorId":3581730511233431,"author":{"id":3581730511233431,"authorId":3581730511233431,"name":"ToTheM00N","avatar":"https://static.tigerbbs.com/7b77b689650adddd8a8560dc89fcb930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9079973140,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}